LivaNova PLC LIVN
89.99 USD -1.15 (-1.26%)
At closeNov 6, 2026, 4:00 PM EST
89.99 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
88.42 Day range 91.51
49.57 52-week range 94.19
- YTD
- +46.25%
- 1 year
- +81.54%
News
benzinga.com Baird Maintains Outperform on LivaNova, Raises Price Target to $111 Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $95 to $111.
seekingalpha.com LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
marketbeat.com LivaNova Q3 Earnings Call Highlights LivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology…
benzinga.com Needham Maintains Buy on LivaNova, Raises Price Target to $112 Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $93 to $112.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
zacks.com LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for LivaNova (LIVN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
zacks.com LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates LivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.
benzinga.com LivaNova Raises FY2026 Adj EPS Guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 Est; Raises FY2026 Sales Guidance from $1.499B-$1.513B to $1.513B-$1.527B vs $1.522B Est LivaNova (NASDAQ:LIVN) raises FY2026 Adj EPS guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 analyst estimate. Raises FY2026 sales outlook from $1.499 billion-$1.513 billion to $1.513…- benzinga.com LivaNova Q3 Adj. EPS $1.23 Beats $1.06 Estimate, Sales $393.100M Beat $381.067M Estimate LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.23 per share which beat the analyst consensus estimate of $1.06 by 16.04 percent. This is a 10.81 percent increase over earnings of $1.11 per…
businesswire.com LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026…
benzinga.com LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results…